Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update

Abstract

Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There are 72 FDA-approved therapeutic agents that target about two dozen different protein kinases and three of these drugs were approved in 2022. Of the approved drugs, twelve target protein-serine/threonine protein kinases, four are directed against dual specificity protein kinases (MEK1/2), sixteen block nonreceptor protein-tyrosine kinases, and 40 target receptor protein-tyrosine kinases. The data indicate that 62 of these drugs are prescribed for the treatment of neoplasms (57 against solid tumors including breast, lung, and colon, ten against nonsolid tumors such as leukemia, and four against both solid and nonsolid tumors: acalabrutinib, ibrutinib, imatinib, and midostaurin). Four drugs (abrocitinib, baricitinib, tofacitinib, upadacitinib) are used for the treatment of inflammatory diseases (atopic dermatitis, psoriatic arthritis, rheumatoid arthritis, Crohn disease, and ulcerative colitis). Of the 72 approved drugs, eighteen are used in the treatment of multiple diseases. The following three drugs received FDA approval in 2022 for the treatment of these specified diseases: abrocitinib (atopic dermatitis), futibatinib (cholangiocarcinomas), pacritinib (myelofibrosis). All of the FDA-approved drugs are orally effective with the exception of netarsudil, temsirolimus, and trilaciclib. This review summarizes the physicochemical properties of all 72 FDA-approved small molecule protein kinase inhibitors including lipophilic efficiency and ligand efficiency.

Keywords: Abrocitinib (PubChem CID: 78323835); Asciminib (PubChem CID: 72165228); Atopic dermatitis; Cholangiocarcinoma; Chronic myelogenous leukemia; Dasatinib (PubChem CID: 3062316); Futibatinib (PubChem CID: 71621331); Ibrutinib (PubChem CID: 24821094); Imatinib (PubChem CID: 5291); Myelofibrosis, Protein kinase inhibitor classification; Pacritinib (PubChem CID: 46216796); Ruxolitinib (PubChem CID: 25126798); Sorafenib (PubChem CID: 216239); Sunitinib (PubChem CID: 5329102); Treatment-free remission.